Geriatrik Üroonkolojinin Geleceği

United Nations, Department of Economic and Social Affairs. World Population Ageing 2020 Highlights. New York: UN; 2020.

Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics for older adults, 2023. CA: A Cancer Journal for Clinicians. 2023;73(6):410–436. doi:10.3322/caac.21779

Hemelaar M, van der Graaf WTA, Alfano CM, et al. Age distribution of urological cancers: a global perspective. European Urology. 2022;82(4):423–430. doi:10.1016/j.eururo.2022.05.001

Mohile SG, Dale W, Hurria A, et al. Geriatric oncology assessment of the older person with cancer. Journal of Clinical Oncology. 2018;36(22):2299–2303. doi:10.1200/JCO.2018.78.7719

Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems in elderly cancer patients: SIOG recommendations. Annals of Oncology. 2015;26(2):288–300. doi:10.1093/annonc/mdu477

Sanoff HK, Deal AM, Krishnamurthi N, et al. Biological aging and cancer outcomes in older patients: a population-based study. Journal of the National Cancer Institute. 2019;111(7):711–719. doi:10.1093/jnci/djy192

Gross CP, Mallory RM, Heiat A, et al. Systematic review of age bias in clinical trials. JAMA. 2005;293(18):2384–2390. doi:10.1001/jama.293.18.2384

El Necchi A, Schipani S, Bechis SK, et al. Comprehensive geriatric assessment predicts tolerance of prostate cancer therapy. Journal of Geriatric Oncology. 2021;12(5):848–856. doi:10.1016/j.jgo.2021.05.003

Pawelec G, Goldeck D, Derhovanessian E. Inflammation and T‐cell senescence in the elderly: implications for cancer immunotherapy. Journal of Leukocyte Biology. 2021;109(6):1237–1248. doi:10.1002/JLB.3RU0520-379R

Schvartsman G, Chen L, Owen DH, et al. Impact of age on efficacy and safety of PD-1 inhibitors in urothelial cancer. Journal of Clinical Oncology. 2020;38(29):3378–3385. doi:10.1200/JCO.20.00768

Cheng DT, Lovejoy AF, Hong DS, et al. Practical implications of DNA damage repair deficiency in elderly cancer patients. Cancer Discovery. 2019;9(10):1249–1257. doi:10.1158/2159-8290.CD-19-0191

Abida W, Campbell D, Patnaik A, et al. Olaparib in metastatic castration resistant prostate cancer with DNA repair mutations. The New England Journal of Medicine. 2020;383(20):2091–2102. doi:10.1056/NEJMoa2022483

Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in adults: foci include sarcopenia and frailty metrics. The Lancet Oncology. 2013;14(4):e214–e223. doi:10.1016/S1470-2045(12)70468-5

Gill TM, Allore HG, Thibault DP, et al. The management of older adults with frailty and cancer: expert consensus. Journal of Geriatric Oncology. 2021;12(4):556–567. doi:10.1016/j.jgo.2021.01.015

Klepin HD, Geiger AM, Tooze J, et al. Feasibility of geriatric assessment in community oncology clinics. Journal of Clinical Oncology. 2011;29(27):3552–3559. doi:10.1200/JCO.2010.32.5418

McNally E, Keating N, Sheill G, et al. Impact of geriatric intervention on chemotherapy outcome: a meta-analysis. British Journal of Cancer. 2022;126(8):1117–1125. doi:10.1038/s41416-021-01690-5

Soubeyran P, Bellera C, Goyard J, et al. ONCODAGE study: G8 score predicts vulnerability in elderly cancer patients. PLoS One. 2014;9(12):e115060. doi:10.1371/journal.pone.0115060

Rennert G, Choueiri TK, Teh JB, et al. Comorbidity burden and prostate cancer outcomes post-radical prostatectomy. Urology. 2020;136:99–105. doi:10.1016/j.urology.2019.09.056

LeBlanc TW, Denduluri N, Pai Sonmez N, et al. Polypharmacy and potential inappropriate medication use in older adults with cancer. Journal of Clinical Oncology. 2015;33(13):1406–1414. doi:10.1200/JCO.2014.57.1294

Mottet N, van den Bergh RCN, Briers E, et al. EAU–ESTRO–SIOG guidelines on prostate cancer—2023 update. European Urology. 2023;83(3):242–266. doi:10.1016/j.eururo.2022.10.010

Omberg L, Brasso K, Trolle Nielsen S, et al. PSA kinetics in elderly men: implications for biopsy decisions. European Urology Oncology. 2021;4(4):630–638. doi:10.1016/j.euo.2020.11.005

Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer (ProtecT): a randomized trial. The New England Journal of Medicine. 2023;388(19):1829–1839. doi:10.1056/NEJMoa2300248

Coughlin GD, McNeill SA, Young EE, et al. Robotic radical prostatectomy in men aged 75+: functional and oncologic outcomes. Urologic Oncology. 2018;36(10):473.e21–473.e28. doi:10.1016/j.urolonc.2018.05.042

de Bono JS, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. The New England Journal of Medicine. 2020;382(22):2091–2102. doi:10.1056/NEJMoa1911440

Hofman MS, Emmett L, Sandhu S, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. The New England Journal of Medicine. 2021;385(12):1091–1103. doi:10.1056/NEJMoa2107322

Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular disease. JAMA. 2011;306(21):2359–2366. doi:10.1001/jama.2011.1775

Alibhai SMH, Timilshina N, Barclay J, et al. Randomized trial of intermittent vs continuous ADT in elderly men with prostate cancer. The Lancet Oncology. 2022;23(4):540–549. doi:10.1016/S1470-2045(21)00760-X

Filson CP, Weiner AB, Morgan TM, et al. Hematuria evaluation in older adults: delays in bladder cancer diagnosis. The Journal of Urology. 2017;197(2):530–535. doi:10.1016/j.juro.2016.08.102

Witjes JA, Babjuk M, Bellmunt J, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer—2023 update. European Urology. 2023;83(3):299–312. doi:10.1016/j.eururo.2022.10.038

Bajorin DF, Witjes JA, Gschwend JE, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. The New England Journal of Medicine. 2021;384(1):75–87. doi:10.1056/NEJMoa2016345

Ljungberg B, Albiges L, Bensalah K, et al. European Association of Urology guidelines on renal cell carcinoma—2022 update. European Urology. 2022;82(6):605–615. doi:10.1016/j.eururo.2022.08.027

van Poppel H, Da Pozzo L, Albrecht W, et al. A randomized trial comparing open vs laparoscopy nephrectomy in elderly patients. European Urology. 2018;74(3):293–301. doi:10.1016/j.eururo.2018.05.017

Motzer RJ, Jonasch E, Agarwal N, et al. NCCN guidelines insights: renal cell carcinoma, version 1.2023. Journal of the National Comprehensive Cancer Network. 2023;21(1):1–23. doi:10.6004/jnccn.2023.0001

Decoster L, Mohile S, Van Puyvelde K, et al. Screening tools to identify older cancer patients for CGA: systematic review. Annals of Oncology. 2015;26(2):288–300. doi:10.1093/annonc/mdu477

Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment. Journal of Clinical Oncology. 2014;32(24):2595–2603. doi:10.1200/JCO.2014.57.8951

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19(6):371–384. doi:10.1038/nrg.2017.104

Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. Journal of the American Geriatrics Society. 1968;16(5):622–626. doi:10.1111/j.1532-5415.1968.tb04103.x

Daskivich TJ, Fan X, Koyama T, et al. Perioperative outcomes after prostatectomy by CCI score. Urologic Oncology. 2019;37(6):360–367. doi:10.1016/j.urolonc.2019.02.022

Smedley BD, Stith AY, Nelson AR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington (DC): Institute of Medicine; 2019.

Gabrilovich M, Da Silva MC, et al. Robotic surgery in frail elderly: safety and efficacy review. Surgical Endoscopy. 2021;35(7):3270–3281. doi:10.1007/s00464-020-07916-z

Herlemann A, Gandaglia G, Pasyk KA, et al. Robot-assisted prostatectomy in patients >75 years: perioperative and long-term outcomes. Urology. 2020;145:247–253. doi:10.1016/j.urology.2020.01.025

Gandhi N, Goldberg H, Wu S, et al. Robotic cystectomy in elderly patients: outcomes and complications. European Urology Focus. 2022;8(4):868–875. doi:10.1016/j.euf.2021.08.008

Khan MS, Traboulsi S, Khan F, et al. Minimally invasive nephrectomy in elderly: a systematic review and meta-analysis. BJU International. 2023;131(3):295–305. doi:10.1111/bju.16021

Evered L, Silbert B, Knopman DS, et al. Nomenclature consensus in postoperative cognitive dysfunction and delirium: STROPS. Anesthesiology. 2018;129(4):872–879. doi:10.1097/ALN.0000000000002131

Chang SS, Baumgarten AS, Gillitzer R, et al. Long-term outcomes of robotic surgery in elderly urologic oncology. The Journal of Urology. 2021;205(2):420–428. doi:10.1097/JU.0000000000001871

Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International. 2010;106(4):462–469. doi:10.1111/j.1464-410X.2010.09334.x

Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annals of Oncology. 2012;23(8):2166–2172. doi:10.1093/annonc/mdr587

Li C, Marcu LG, van Doorn T, et al. Artificial intelligence in prostate cancer management: applications and challenges. Critical Reviews in Oncology/Hematology. 2022;169:103552. doi:10.1016/j.critrevonc.2021.103552

Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. Journal of Clinical Oncology. 2015;33(32):3826–3833. doi:10.1200/JCO.2015.63.0319

Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. The New England Journal of Medicine. 2010;363(8):733–742. doi:10.1056/NEJMoa1000678

Soto-Perez-de-Celis E, de Glas NA, Hsu T, et al. Global geriatric oncology: achievements and challenges. Journal of Geriatric Oncology. 2020;11(5):837–844. doi:10.1016/j.jgo.2020.02.005